
Is it time to broaden use of multigene panel testing in colorectal cancer patients?
Sarah Coughlin explains her study and its findings: across all ages, panel sizes, and races/ethnicities, the rate of clinically actionable variants was 7.8 percent or greater – supporting an expanded role for multigene panel testing in CRC patients.